UCB ups FY view; almost doubles H1 profit on strong drug sales
Belgian pharmaceutical company UCB (Euronext Brussels: UCB) raised its outlook for 2015 as first-half sales beat estimates boosted by revenue from three major drugs.
The company said it sees 2015 revenue in the range of 3.65 billion euros ($4 billion) to 3.75 billion euros ($4.1 billion), with earnings per share between 1.90 euros ($2.08) and 2.05 euros ($2.24).
UCB reported first-half profit of 267 million euros ($292 million), up 94% year on year. Revenue was boosted by sales of its top line drugs Cimzia (certolizumab pegol), Vimpat (lacosamide) and Neupro (rotigotine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze